Impedimed Ltd has released a press release.
Impedimed: Interim Results of PREVENT Trial
Filed with ASX ·
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings Call6ix hasn’t read this filing yet.
Earlier from Impedimed
- US FDA 510(k) Clearance for Bilateral Lymphoedema Assessment
- ImpediMed & Sharp HealthCare Sign Agreement for SOZO
- Appendix 4C - Quarter ended 31 December 2017
- US FDA 510(k) Clearance Issued for CHF Monitoring with SOZO
- L-Dex Abstracts to be Presented at Breast Cancer Symposium
Later from Impedimed
- Appendix 4C - Quarter ended 31 March 2018
- Appendix 4C - Quarter ended 30 June 2018
- PREVENT Trial Results Published - Outstanding Initial Data
- L-Dex Suggested as a New Standard of Care
- Response to ASX Aware Query
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed